Limitations, agreements, and source contact

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma · Source last updated 2026-06-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

limitations And Caveats

description

The study was targeted to accrue 130 patients, but closed early for futility. Early termination leading to small numbers of subjects analyzed.

point Of Contact

email

kurasa@nrgoncology.org

organization

NRG Oncology Statistics and Data Management Center - Buffalo

phone

(716) 845-5702

title

Angela M. Kuras, Associate Director of Administration and Operations

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice